JP6722076B2 - 薬物有害事象を予測するためのコンピュータ実装方法、コンピュータ・プログラム製品、および処理システム - Google Patents
薬物有害事象を予測するためのコンピュータ実装方法、コンピュータ・プログラム製品、および処理システム Download PDFInfo
- Publication number
- JP6722076B2 JP6722076B2 JP2016188561A JP2016188561A JP6722076B2 JP 6722076 B2 JP6722076 B2 JP 6722076B2 JP 2016188561 A JP2016188561 A JP 2016188561A JP 2016188561 A JP2016188561 A JP 2016188561A JP 6722076 B2 JP6722076 B2 JP 6722076B2
- Authority
- JP
- Japan
- Prior art keywords
- drug
- adverse event
- candidate
- adverse
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 68
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 title claims description 31
- 238000012545 processing Methods 0.000 title claims description 19
- 238000004590 computer program Methods 0.000 title claims description 11
- 229940079593 drug Drugs 0.000 claims description 248
- 239000003814 drug Substances 0.000 claims description 248
- 230000002411 adverse Effects 0.000 claims description 30
- 230000007246 mechanism Effects 0.000 claims description 8
- 238000007477 logistic regression Methods 0.000 claims description 7
- 238000010801 machine learning Methods 0.000 claims description 4
- 230000010365 information processing Effects 0.000 claims 1
- 238000010586 diagram Methods 0.000 description 14
- 230000006870 function Effects 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- 230000036541 health Effects 0.000 description 9
- 230000009471 action Effects 0.000 description 6
- 206010061623 Adverse drug reaction Diseases 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 238000007726 management method Methods 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 238000012549 training Methods 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 238000004891 communication Methods 0.000 description 3
- 238000011524 similarity measure Methods 0.000 description 3
- 206010010071 Coma Diseases 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000008406 drug-drug interaction Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000036647 Medication errors Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 description 1
- 229960003655 bromfenac Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012517 data analytics Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000005055 memory storage Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000013468 resource allocation Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000000547 structure data Methods 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Information and communication technology [ICT] specially adapted for implementation of business processes of specific business sectors, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Social work or social welfare, e.g. community support activities or counselling services
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/30—Prediction of properties of chemical compounds, compositions or mixtures
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Primary Health Care (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Business, Economics & Management (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Data Mining & Analysis (AREA)
- Theoretical Computer Science (AREA)
- Tourism & Hospitality (AREA)
- Child & Adolescent Psychology (AREA)
- General Physics & Mathematics (AREA)
- Databases & Information Systems (AREA)
- Economics (AREA)
- Human Resources & Organizations (AREA)
- Marketing (AREA)
- Strategic Management (AREA)
- Physics & Mathematics (AREA)
- General Business, Economics & Management (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Computational Biology (AREA)
- Computing Systems (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Description
1)薬物dおよび類似度メトリクsimについて、較正特徴FeatureAvg(d,sim)は、他のすべての既知の薬物に対する薬物dの平均(すなわち、算術平均)類似度を見積もる。それは、以下のように計算される。
FeatureAvg(d, sim) = ΣX∈Drugs-{d}sim(d,X)/(|Drugs|-1)、但し、Drugsは、すべての薬物のセットであり、|Drugs|は、薬物の総数である。
2)薬物dおよび類似度メトリクsimについて、較正特徴FeatureStd(d,sim)は、ランダム変数Y = sim(d,X)の標準偏差を見積もり、但し、Xは、dとは異なる薬物である(すなわち、X∈Drugs-{d})。
IDF(t,Drugs) = log((│Drugs│+1)/(DF(t, Drugs)+1))
但し、Drugsは、すべての薬物のセットを表し、tは、作用機構または生理作用などの特徴を表し、そして、DF(t, Drugs)は、特徴tを有するDrugsにおける薬物の数を表す。例示的実施形態では、重み付けは、コサイン類似度を計算する前など、特徴類似度を計算する前に行われる。
12 コンピュータ・システム/サーバ
14 外部デバイス
16 プロセッサまたは処理装置
18 バス
20 ネットワーク・アダプタ
22 入力/出力インターフェース
24 ディスプレイ
28 システム・メモリ
30 ランダム・アクセス・メモリ(RAM)
32 キャッシュ・メモリ
34 ストレージ・システム
40 プログラム/ユーティリティ
42 プログラム・モジュール
50 クラウド・コンピューティング・ノード
54A 携帯電話
54B デスクトップ・コンピュータ
54C ラップトップ・コンピュータ
54N 自動車コンピュータ・システム
60 ハードウェアおよびソフトウェア層
62 仮想化層
64 管理層
66 作業負荷層
102 データ・サービス・ネットワーク・システム
300 アプリケーション・ユーザ・インターフェース
302 入力
304 出力
Claims (5)
- コンピュータの情報処理により薬物有害事象を予測する方法であって、
1つ以上の薬物データベースから既知の薬物データを受信するステップと、
候補薬物、薬物ペア、および候補薬物と患者のペア(候補薬物―患者ペア)のうちの1つまたは複数を受信するステップと、
プロセッサによって、有害事象の有害事象予測評価を計算するステップであって、
複数の薬物ペアと、前記複数の薬物ペアについて関連度を表す特徴類似性度を含む、1つ以上の特徴類似性テーブルを構築するステップ、
既知の有害事象の特徴と関連する既知の薬物または薬物ペアを含む1つ以上の有害事象特徴テーブルを作成するステップであって、前記有害事象の特徴には、有害薬物の性質、原因、機構、および重症度の1つ以上を含む、ステップと
前記1つ以上の特徴類似性テーブルおよび前記1つ以上の有害事象特徴テーブルに基づいて1つ以上の多次元候補有害事象テーブルを構築するステップと、
機械学習ロジスティック回帰モデルによって生成された、1つ以上の有害事象特徴テーブルと1つ以上の多次元候補有害事象テーブルから抽出された複数の特徴を含む特徴ベクトルに基づいて、有害事象予測評価を決定する候補薬物、薬物ペア、候補薬物―患者ペアの1つ以上の有害薬物事象の信頼レベルを表す有害事象予測評価を決定するステップと、
前記有害事象予測評価と1つ以上の潜在的な有害事象を出力するステップと、
1つ以上の多次元薬物プロファイルを構築するステップであって、前記多次元薬物プロファイルが、1つ以上の有害事象予測評価に基づき、候補薬物、薬物のペア、および候補薬物―患者ペアの1つ以上の複数の有害事象特徴を含む、ステップと
を含む、方法。 - 前記方法が、候補薬物、薬物ペア、および候補薬物―患者ペアのうちの1つまたは複数の1つまたは複数の特徴類似性を計算し、個別に複数の特徴類似性を重み付けするステップをさらに含む、請求項1に記載の方法。
- 請求項1〜2の何れか1項に記載の方法の各ステップを、コンピュータに実行させる、コンピュータ・プログラム。
- 請求項3記載の前記コンピュータ・プログラムを、コンピュータ可読媒体に記録した、コンピュータ可読媒体。
- 請求項1〜2の何れか1項に記載の方法の各ステップを、コンピュータ・ハードウェアによる手段として構成した、処理システム。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/920,327 US20170116376A1 (en) | 2015-10-22 | 2015-10-22 | Prediction of adverse drug events |
US14/920327 | 2015-10-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017084350A JP2017084350A (ja) | 2017-05-18 |
JP6722076B2 true JP6722076B2 (ja) | 2020-07-15 |
Family
ID=57539940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016188561A Active JP6722076B2 (ja) | 2015-10-22 | 2016-09-27 | 薬物有害事象を予測するためのコンピュータ実装方法、コンピュータ・プログラム製品、および処理システム |
Country Status (3)
Country | Link |
---|---|
US (2) | US20170116376A1 (ja) |
JP (1) | JP6722076B2 (ja) |
GB (1) | GB2544860A (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190095584A1 (en) * | 2017-09-26 | 2019-03-28 | International Business Machines Corporation | Mechanism of action derivation for drug candidate adverse drug reaction predictions |
KR20190065128A (ko) | 2017-12-01 | 2019-06-11 | 한국과학기술원 | 약물의 구조 정보를 이용한 약물-약물 또는 약물-음식 상호작용 예측 방법 |
US11120913B2 (en) | 2018-01-24 | 2021-09-14 | International Business Machines Corporation | Evaluating drug-adverse event causality based on an integration of heterogeneous drug safety causality models |
EP3525213A1 (en) * | 2018-02-07 | 2019-08-14 | Koninklijke Philips N.V. | Identifying adverse events |
US11164678B2 (en) * | 2018-03-06 | 2021-11-02 | International Business Machines Corporation | Finding precise causal multi-drug-drug interactions for adverse drug reaction analysis |
CN111383725B (zh) * | 2018-12-28 | 2023-04-28 | 国家食品药品监督管理总局药品评价中心 | 不良反应数据鉴别方法、装置、电子设备及可读介质 |
US11568018B2 (en) * | 2020-12-22 | 2023-01-31 | Dropbox, Inc. | Utilizing machine-learning models to generate identifier embeddings and determine digital connections between digital content items |
EP4068295A1 (en) * | 2021-03-29 | 2022-10-05 | Siemens Healthcare GmbH | Clinical decision support system for estimating drug-related treatment optimization concerning inflammatory diseases |
CN113362886B (zh) * | 2021-07-26 | 2022-04-15 | 北京航空航天大学 | 基于药物显隐式特征融合相似性的不良反应预测方法 |
WO2023126832A1 (en) * | 2021-12-30 | 2023-07-06 | Pfizer Inc. | Digital medicine companion for cdk inhibitor medications for cancer patients |
WO2024019081A1 (ja) * | 2022-07-22 | 2024-01-25 | 富士フイルム株式会社 | 情報処理装置、情報処理装置の作動方法、および情報処理装置の作動プログラム |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6219674B1 (en) * | 1999-11-24 | 2001-04-17 | Classen Immunotherapies, Inc. | System for creating and managing proprietary product data |
US6551243B2 (en) * | 2001-01-24 | 2003-04-22 | Siemens Medical Solutions Health Services Corporation | System and user interface for use in providing medical information and health care delivery support |
US8095379B2 (en) * | 2003-12-30 | 2012-01-10 | Cerner Innovation, Inc. | System and method for preemptive determination of the potential for an atypical clinical event related to the administering of medication |
JP2010505155A (ja) * | 2006-08-22 | 2010-02-18 | リード ホース テクノロジーズ インコーポレイテッド | 医療評価支援システムと方法 |
US8099298B2 (en) * | 2007-02-14 | 2012-01-17 | Genelex, Inc | Genetic data analysis and database tools |
CN102483818A (zh) * | 2009-04-22 | 2012-05-30 | 领头马科技股份有限公司 | 人工智能辅助的医疗参考系统和方法 |
US8543422B2 (en) * | 2011-04-04 | 2013-09-24 | International Business Machines Corporation | Personalized medical content recommendation |
US9305267B2 (en) * | 2012-01-10 | 2016-04-05 | The Board Of Trustees Of The Leland Stanford Junior University | Signal detection algorithms to identify drug effects and drug interactions |
US20130191161A1 (en) * | 2012-01-24 | 2013-07-25 | Vimedicus, Inc. | Patient data input and access system that enhances patient care |
JP6410289B2 (ja) * | 2014-03-20 | 2018-10-24 | 日本電気株式会社 | 医薬品有害事象抽出方法及び装置 |
US10803144B2 (en) * | 2014-05-06 | 2020-10-13 | International Business Machines Corporation | Predicting drug-drug interactions based on clinical side effects |
-
2015
- 2015-10-22 US US14/920,327 patent/US20170116376A1/en not_active Abandoned
- 2015-11-30 US US14/953,590 patent/US20170116390A1/en not_active Abandoned
-
2016
- 2016-09-23 GB GB1616211.7A patent/GB2544860A/en not_active Withdrawn
- 2016-09-27 JP JP2016188561A patent/JP6722076B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
US20170116376A1 (en) | 2017-04-27 |
GB201616211D0 (en) | 2016-11-09 |
GB2544860A (en) | 2017-05-31 |
JP2017084350A (ja) | 2017-05-18 |
US20170116390A1 (en) | 2017-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6722076B2 (ja) | 薬物有害事象を予測するためのコンピュータ実装方法、コンピュータ・プログラム製品、および処理システム | |
JP7343453B2 (ja) | 配列に基づいた遺伝子検査の解釈および報告のための方法およびシステム | |
US20190252047A1 (en) | Electronic Medical Record Summary and Presentation | |
Ma et al. | Protein threading using context-specific alignment potential | |
Luo et al. | Big data application in biomedical research and health care: a literature review | |
Buske et al. | PhenomeCentral: a portal for phenotypic and genotypic matchmaking of patients with rare genetic diseases | |
Saraiya et al. | Visualizing biological pathways: requirements analysis, systems evaluation and research agenda | |
Huang et al. | Promises and challenges of big data computing in health sciences | |
Cheng et al. | OAHG: an integrated resource for annotating human genes with multi-level ontologies | |
Grossman | Data lakes, clouds, and commons: a review of platforms for analyzing and sharing genomic data | |
US20120072232A1 (en) | Systems and Methods for Using Online Resources to Design a Clinical Study and Recruit Participants | |
Hoffman et al. | Electronic medical records and personalized medicine | |
Chicco et al. | Survival prediction of patients with sepsis from age, sex, and septic episode number alone | |
Kudtarkar et al. | Cost-effective cloud computing: a case study using the comparative genomics tool, roundup | |
Ocaña et al. | Parallel computing in genomic research: advances and applications | |
Fahr et al. | A review of the challenges of using biomedical big data for economic evaluations of precision medicine | |
WO2016141045A2 (en) | Detection and visualization of temporal events in a large-scale patient database | |
Xiao et al. | An MCEM framework for drug safety signal detection and combination from heterogeneous real world evidence | |
Juan-Blanco et al. | IntSide: a web server for the chemical and biological examination of drug side effects | |
Azuaje et al. | Computational biology for cardiovascular biomarker discovery | |
Agapito et al. | BioPAX-Parser: parsing and enrichment analysis of BioPAX pathways | |
US20190096524A1 (en) | Mechanism of action derivation for drug candidate adverse drug reaction predictions | |
Baker et al. | Comprehensive comparison of cloud-based NGS data analysis and alignment tools | |
Cardoso et al. | A collection of benchmark data sets for knowledge graph-based similarity in the biomedical domain | |
US20210174912A1 (en) | Data processing systems and methods for repurposing drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190225 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191224 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200121 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200417 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200616 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200619 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6722076 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |